Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.37 |
| ▸ | CNR2 | P34972 | 4/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 12/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.35 |
| ▸ | PTPRA | P18433 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2937650 | 0.96 | PTPN1 (0.40) | CNR1CNR2PTPN1PTPN2 | |
| SCHEMBL3929110 | 0.93 | CNR1 (0.41) | CNR1CNR2PTPN1 | |
| SCHEMBL3217932 | 0.91 | CNR1 (0.41) | CNR1CNR2PTPN1PTPN2PTPRA | |
| SCHEMBL2930479 | 0.89 | CNR1 (0.41) | CNR1CNR2PTPN1PTPN2PTPRA | |
| SCHEMBL3201537 | 0.86 | CNR1 (0.43) | CNR1CNR2PTPN1 | |
| SCHEMBL3220485 | 0.86 | PTPN1 (0.43) | CNR1CNR2PTPN1 | |
| SCHEMBL2930481 | 0.83 | CNR1 (0.39) | CNR1CNR2PTPN1 | |
| SCHEMBL2933664 | 0.83 | CNR1 (0.46) | CNR1CNR2PTPN1 | |
| SCHEMBL3216067 | 0.83 | CNR1 (0.42) | CNR1CNR2PTPN1 | |
| SCHEMBL4127080 | 0.83 | CNR1 (0.49) | CNR1CNR2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2089026-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | Novartis AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008070552-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | NOVARTIS AG (CH) | 2008-06-12 | — | — | WO | disclosed |